Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2002; 40:1153-1159
© 2002 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baba, A.
Right arrow Articles by Ogawa, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baba, A.
Right arrow Articles by Ogawa, S.

CLINICAL STUDY: ELECTROPHYSIOLOGY

Autoantibodies produced against sarcolemmal Na-K-ATPase: possible upstream targets of arrhythmias and sudden death in patients with dilated cardiomyopathy

Akiyasu Baba, MD, PhD*,*, Tsutomu Yoshikawa, MD{dagger} and Satoshi Ogawa, MD{dagger}

* Department of Medicine, Kitasato Institute Hospital, Tokyo, Japan
{dagger} Cardiopulmonary Division, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.

Manuscript received November 5, 2001; revised manuscript received April 25, 2002, accepted June 19, 2002.

* Reprint requests and correspondence: Akiyasu Baba, MD, Department of Medicine, Kitasato Institute Hospital, 5-9-1 Shirokane Minato-ku, Tokyo 108-8642, Japan.
baba-a{at}kitasato.or.jp

OBJECTIVES: We sought to test the hypothesis that autoantibodies (Abs) produced against sarcolemmal Na-K-ATPase play a role in the development of ventricular tachycardia (VT) and cardiac sudden death in patients with dilated cardiomyopathy (DCM).

BACKGROUND: Autoimmunity is one of the mechanisms of pathogenesis of DCM as well as virus infection and genetic predisposition.

METHODS: One hundred patients with DCM and age-matched control subjects (CTL) were screened for Abs produced against Na-K-ATPase by using enzyme-linked immunosorbent assay.

RESULTS: Abs were detected in 26 DCM and 2 CTL patients. Na-K-ATPase activity in the presence of patient IgG was lower in DCM with Abs than without Abs, but there was no difference between two groups in CTL. Western blots showed that Abs recognized the alpha subunit of Na-K-ATPase, and 3H-ouabain bindings in the presence of patient IgG showed that dissociation constant was higher in DCM with Abs than without Abs. No difference existed between subjects with regard to age, gender, New York Heart Association functional class, cardiac function, or neurohormone levels, except for plasma norepinephrine, which was higher in patients with Abs than without Abs. VTs were more common in patients with Abs than without Abs, and multiple logistic regression analysis demonstrated that the presence of Abs, but not plasma norepinephrine, was an independent predictor for the occurrence of VT. Cardiac sudden death was independently predicted by the presence of Abs, as well as poor systolic function.

CONCLUSIONS: We conclude that there are Abs produced against sarcolemmal Na-K-ATPase in patients with DCM and that Abs could be responsible for the electrical instability in some cases.

Abbreviations and Acronyms
  Ab/Abs
  autoantibody/autoantibodies
  CHF
  congestive heart failure
  DCM
  dilated cardiomyopathy
  ELISA
  enzyme-linked immunosorbent assay
  LVEF
  left ventricular ejection fraction
  NSVT
  non-sustained ventricular tachycardia
  NYHA
  New York Heart Association
  PNE
  plasma norepinephrine
  PVC
  premature ventricular complex
  VT
  ventricular tachycardia




This article has been cited by other articles:


Home page
Eur Heart JHome page
F. Leuschner, J. Li, S. Goser, L. Reinhardt, R. Ottl, P. Bride, J. Zehelein, G. Pfitzer, A. Remppis, E. Giannitsis, et al.
Absence of auto-antibodies against cardiac troponin I predicts improvement of left ventricular function after acute myocardial infarction
Eur. Heart J., August 2, 2008; 29(16): 1949 - 1955.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
A L. Caforio, L Daliento, A Angelini, S Bottaro, A Vinci, G Dequal, F Tona, S Iliceto, G Thiene, and W J McKenna
Autoimmune myocarditis and dilated cardiomyopathy: focus on cardiac autoantibodies
Lupus, September 1, 2005; 14(9): 652 - 655.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
A. Staudt, Y. Staudt, M. Dorr, M. Bohm, F. Knebel, A. Hummel, L. Wunderle, M. Tiburcy, K. D. Wernecke, G. Baumann, et al.
Potential role of humoral immunity in cardiac dysfunction of patients suffering from dilated cardiomyopathy
J. Am. Coll. Cardiol., August 18, 2004; 44(4): 829 - 836.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
A. Baba, T. Yoshikawa, Y. Fukuda, T. Sugiyama, M. Shimada, M. Akaishi, K. Tsuchimoto, S. Ogawa, and M. Fu
Autoantibodies against M2-muscarinic acetylcholine receptors: new upstream targets in atrial fibrillation in patients with dilated cardiomyopathy
Eur. Heart J., July 1, 2004; 25(13): 1108 - 1115.
[Abstract] [Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement